Hospital- and clinic-based approaches to the treatment of ARVI in children

Abstract

The objectives of the study conducted at the Research Institute of Children’s Infections of the Federal Medical and Biological Agency was to analyze the changes in the severity of clinical syndromes and isolation of influenza/ARVI viruses during treatment with Kagocel®. The study group consisted of 80 children aged 3–11 years who were hospitalized with symptoms of influenza and ARVI, whose complex therapy included Kagocel®. The study showed a significant (p <0.001) reduction of fever on day 3 of therapy with normalization of body temperature from day 4. The intoxication syndrome was in most cases relieved by day 4 (p <0.001). Catarrhal syndrome significantly (p <0.01) decreased from day 3 to day 7 of therapy. The elimination of respiratory viruses based on PCR results by day 5–6 of therapy with Kagocel amounted to 57.1%. The most frequently observed reduction of isolated viruses was recorded for influenza B, A and RS-virus (86, 53.8, 71.4% respectively), and rhinovirus was eliminated less frequently (33.3%). Comparison of the results of the study with the literature data demonstrated correlation of the changes in clinical syndromes of influenza/ARVI if Kagocel was included in therapy, as well as its good tolerability in children from three years at hospitals and in outpatient settings.